Clinical Question
What is the current FDA regulatory status of commonly compounded peptides, and what safety signals have emerged from clinical trials and postmarketing surveillance?
Evidence Snapshot
- Regulatory Status: Multiple peptides including BPC-157, Thymosin Alpha-1, and TB-500 are currently classified as Category 2 bulk substances (as of March 2026), making them ineligible for routine compounding under Section 503A.
- Clinical Trials: Phase III data for Semaglutide show a 14.9% weight loss (STEP 1) and a 20% MACE reduction (SELECT). Tirzepatide demonstrated 22.5% weight loss (SURMOUNT-1). Phase II data for Retatrutide show up to 24.2% weight loss.
- Safety Signals: Strong signals for gastrointestinal events (nausea, vomiting, delayed gastric emptying) and emerging signals for intestinal obstruction, pulmonary aspiration, and NAION have been identified in postmarketing data.
- Warning Letters: Multiple entities including Tailor Made Compounding (2020) and Predator Nutrition (2020) have received FDA warning letters regarding various peptide substances.
What the Research Shows
Regulatory Update and Compounding Eligibility
As of March 2026, the FDA has classified several peptides as Category 2 bulk substances under Section 503A, indicating significant safety risks or a lack of safety data. BPC-157 was placed in Category 2 in September 2023 due to immunogenicity concerns and a lack of safety data. It is currently ineligible for routine compounding and is not listed under 503B due to the absence of a clinical-need exemption.
Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, is not FDA-approved. Its status under 503A was changed in September 2024, when it was removed pending advisory review, though it remains a substance of concern under interim policy. Similarly, peptides such as AOD-9604, Ipamorelin, Selank, and CJC-1295 saw their nominations withdrawn or removed in September 2024.
For CJC-1295, the FDA cited safety issues including increased heart rate. TB-500 remains in Category 2 with the FDA citing immunogenicity risk and a lack of human exposure data. GHK-Cu and GHRP-2 are also listed as Category 2 substances due to immunogenicity concerns.
Clinical Trial Outcomes
Evidence from randomized controlled trials provides data on efficacy for several peptides. In the STEP 1 trial (NCT03548935), Semaglutide achieved 14.9% weight loss in obesity. The SELECT trial (NCT03574597) demonstrated a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide achieved 22.5% weight loss in the SURMOUNT-1 trial (NCT04184622) and showed superiority over semaglutide in the SURMOUNT-5 trial.
Retatrutide Phase II data showed 24.2% weight loss at a 12mg dose, with Phase III (TRIUMPH-3) active and recruiting. Conversely, Thymosin Alpha-1 failed to show mortality reduction in a Phase III sepsis trial (NCT02867267). Tesamorelin demonstrated an 18% reduction in visceral adipose tissue (VAT) in pivotal HIV lipodystrophy trials.
Safety and Postmarketing Surveillance
Safety signals for Semaglutide are primarily gastrointestinal. Strong signals (elevated Relative Reporting Ratio, ROR) exist for nausea and vomiting, which are managed via dose escalation. Delayed gastric emptying is a strong signal noted in Section 5.10 of the label, potentially impacting oral medication absorption and posing pre-surgical concerns.
Emerging signals include intestinal obstruction/ileus and pulmonary aspiration, the latter of which was added to the Ozempic label in 2025 due to risks during general anesthesia. A signal for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) is currently under EMA review (as of January 2025), with 96 cases reported through December 2024 and a median onset of 186 days.
Mechanism
Mechanism of action data was not provided for the regulatory and safety records in the source database. Refer to specific therapeutic evidence summaries for pharmacodynamic information.
Limitations of the Evidence
There is a notable lack of human exposure data for several compounded peptides, including TB-500. The FDA has highlighted significant safety gaps regarding immunogenicity for BPC-157 and GHK-Cu. While Semaglutide has extensive postmarketing data (187,757 GLP-1 RA reports through 2023), signals like suicidal ideation are still under evaluation, with current data not supporting a higher risk than background levels. Several trials, such as the STAY trial for Tesamorelin and TRIUMPH-3 for Retatrutide, are ongoing, and final outcomes are not yet available.
Clinical Takeaway
Regulatory authorities have tightened restrictions on many non-FDA-approved peptides, citing concerns over immunogenicity and lack of safety data. While GLP-1 and GIP/GLP-1 agonists show significant efficacy in weight loss and CV risk reduction, they are associated with strong gastrointestinal safety signals and emerging postmarketing risks that require clinical monitoring, particularly regarding anesthesia and ocular health.
Sources
- REGULATORY STATUS RECORDS: BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2 (March 2026).
- FAERS SAFETY SIGNALS: Semaglutide (Gastrointestinal, Hepatobiliary, Renal, Eye, Psychiatric, Pulmonary signals through Dec 2024/Jan 2025).
- CLINICAL TRIAL RECORDS: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT059290, NCT00451282, STAY Trial, NCT02867267, NCT068211.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.